Form 144 Filer Information UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

Form 144

FORM 144

NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933

144: Filer Information

Filer CIK0001488668Filer CCCXXXXXXXIs this a LIVE or TEST Filing?Is LIVE INFORMATIONSubmission Contact InformationImage: Contact Information

Name Phone E-Mail Address

144: Issuer Information

Name of IssuerBlack Diamond Therapeutics, Inc.SEC File Number001-39200Address of IssuerOne Main Street
14th Floor
Cambridge
MASSACHUSETTS
02142Phone6172520848Name of Person for Whose Account the Securities are To Be SoldDavid EpsteinSee the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose

see the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

Former Board Member

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value		Approximate Date of Sale	Name the Securities Exchange
Class A Common Stock	UBS Financial Services Inc 1000 Harbor Blvd 3rd Floor Weehawken NJ 07086	24621	148464.63	56252794	06/14/2024	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Date you

Nature of

Name of

Amount of

Date of Nature of

Class	Acquired	Acquisition Transaction	Person from Whom Acquired	Acquired	Securities Acquired	Payment	Payment *
Class A Common Stock	09/19/2016 F	Founders Shares	Black Diamond Therapeutics Inc		421665	09/19/2016 Ca	ısh

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
David Epstein 56 Pine St Belmont MA 02478	Black Diamond Therapeutics, Inc.	06/12/2024	62528	383921
David Epstein 56 Pine St Belmont MA 02478	Black Diamond Therapeutics, Inc.	06/13/2024	70853	435745

144: Remarks and Signature

Remarks Date of Notice 06/14/2024 *ATTENTION:*

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature /s/ UBS Financial Services Inc, as attorney-in-fact for David Epstein

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)